Source: Virtual Congress 2020 – COPD phenotypes
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Catterall (Glasgow, United Kingdom), D. Anderson (Glasgow, United Kingdom). Prevalence of alpha-1 antitrypsin deficiency (AATD) in Greater Glasgow and Clyde (GG&C) and current practises. 2431

Member's Comments

No comment yet.

Related content which might interest you: Alpha 1 antitrypsin (A1AT) deficiency in children with asthma in Brazil Source: Eur Respir J 2003; 22: Suppl. 45, 499s Year: 2003 Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006 Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 The Irish national alpha-1 antitrypsin deficiency targeted detection programme Source: Annual Congress 2013 –Epidemiology of respiratory disease Year: 2013 Implementation of screening program for alpha-1 antitrypsin deficiency in Spain Source: Annual Congress 2004 - Emphysema and oxygen therapy Year: 2004 Anxiety in a population tested for alpha-1 antitrypsin deficiency. Source: International Congress 2019 – Genes and environment Year: 2019 Characteristics of zz alpha-1 antitrypsin deficiency patients on the Irish national registry Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Screening of alpha-1 antitrypsin deficiency in a blood donors cohort of the North-Italian area Source: International Congress 2015 – Prevalence of respiratory disease Year: 2015 Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013 Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Description and analysis of the Alpha 1 antitrypsin deficitary genotypes in the southwest area of Galicia (Spain) Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003 Alpha-1 antitrypsin deficiency and lung cancer: Description of a cohort of patients in northwestern Spain Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Decline in health status in alpha1 antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The national alpha-1 antitrypsin deficiency registry in Poland Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Pulmonary rehabilitation (PR) in patients with COPD due to alpha-1 antitrypsin deficiency (AATD): 15 years experience at the Maugeri Institute Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013 Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021